Biblio

Export 2677 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Keyword is A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
M. T. White, Shaw, L. M., and Xie, S. X., “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
M. T. White, Shaw, L. M., and Xie, S. X., “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
M. T. White, Shaw, L. M., and Xie, S. X., “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
W. Wharton, Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., and Kehoe, P. G., “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
W. Wharton, Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., and Kehoe, P. G., “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
W. Wharton, Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., and Kehoe, P. G., “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
W. Wharton, Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., and Kehoe, P. G., “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
W. Wharton, Goldstein, F. C., Tansey, M. G., Brown, A. L., Tharwani, S. D., Verble, D. D., Cintron, A., and Kehoe, P. G., “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
A. M. Wessels, Belger, M., Johnston, J. A., Yu, Y., Rentz, D. M., Dowsett, S. A., and Chandler, J., “Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.”, J Alzheimers Dis, vol. 88, no. 2, pp. 577-588, 2022.
R. Weissmann, Hüttenrauch, M., Kacprowski, T., Bouter, Y., Pradier, L., Bayer, T. A., Kuss, A. W., and Wirths, O., “Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 397-409, 2016.
R. Weissmann, Hüttenrauch, M., Kacprowski, T., Bouter, Y., Pradier, L., Bayer, T. A., Kuss, A. W., and Wirths, O., “Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 397-409, 2016.
R. Weissmann, Hüttenrauch, M., Kacprowski, T., Bouter, Y., Pradier, L., Bayer, T. A., Kuss, A. W., and Wirths, O., “Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 397-409, 2016.
M. S. Weinberg, He, Y., Kivisäkk, P., Arnold, S. E., and Das, S., “Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S355-S365, 2024.
M. S. Weinberg, He, Y., Kivisäkk, P., Arnold, S. E., and Das, S., “Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S355-S365, 2024.
M. S. Weinberg, He, Y., Kivisäkk, P., Arnold, S. E., and Das, S., “Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S355-S365, 2024.
E. X. Wei, Oh, E. S., Harun, A., Ehrenburg, M., and Agrawal, Y., “Vestibular Loss Predicts Poorer Spatial Cognition in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 995-1003, 2018.
M. Wei, Zhao, B., Huo, K., Deng, Y., Shang, S., Liu, J., Li, Y., Ma, L., Jiang, Y., Dang, L., Chen, C., Wei, S., Zhang, J., Yang, H., Gao, F., and Qu, Q., “Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.”, J Alzheimers Dis, vol. 57, no. 3, pp. 899-906, 2017.
M. Wei, Zhao, B., Huo, K., Deng, Y., Shang, S., Liu, J., Li, Y., Ma, L., Jiang, Y., Dang, L., Chen, C., Wei, S., Zhang, J., Yang, H., Gao, F., and Qu, Q., “Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.”, J Alzheimers Dis, vol. 57, no. 3, pp. 899-906, 2017.
E. X. Wei, Oh, E. S., Harun, A., Ehrenburg, M., and Agrawal, Y., “Vestibular Loss Predicts Poorer Spatial Cognition in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 995-1003, 2018.
E. X. Wei, Oh, E. S., Harun, A., Ehrenburg, M., and Agrawal, Y., “Vestibular Loss Predicts Poorer Spatial Cognition in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 995-1003, 2018.
E. M. Weekman and Wilcock, D. M., “Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia.”, J Alzheimers Dis, vol. 49, no. 4, pp. 893-903, 2016.
H. Wang, Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., Edland, S., Jensen, P. H., Shi, M., and Zhang, J., “A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1541-1553, 2018.
H. - F. Wang, Tan, L., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Liu, Y., Wang, C., Tsai, R. M., Jia, J. - P., and Yu, J. - T., “Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.”, J Alzheimers Dis, vol. 51, no. 1, pp. 227-36, 2016.

Pages